alexa Abstract | Comparison of treatment outcome in Rheumatoid Arthritis patients treated with single and two DMARDs in combination with Corticosteroids

International Journal of Drug Development and Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Musculoskeletal disorders impose a considerable burden upon society due to long-term morbidity, disability and treatment costs. Among Musculoskeletal diseases, Rheumatoid Arthritis encumbers patients with a significantly higher individual economic burden. The present study seeks to analyse the Pharmacoeconomics aspects of Rheumatoid Arthritis (RA) and to assess the Quality of Life (QoL) of patients treated with the selected combination of drugs used in the therapy of Rheumatoid Arthritis. The treatment costs vary based on the use of single DMARD, combination DMARDs, biological agents, etc. The design of the study was a prospective and observational study for a period of 12 months in a tertiary care referral hospital in Kerala. All the Rheumatoid Arthritis patients who attended the Rheumatology OPD, with 3 months follow-up and who satisfied the inclusion criteria were included in the study. The Cost effectiveness analysis was done by taking the HAQ - DI score as a measure of effectiveness and the improvement in Quality of Life was measured by using the disease activity parameters like Swollen Joint Count, Tender Joint Count, ESR, duration of morning stiffness, etc. Three groups of Drugs were selected for this study, namely, Group 1: Methotrexate + Corticosteroids, Group 2: Hydroxychloroquine + Corticosteroids, and Group 3: Methotrexate + Hydroxychloroquine + Corticosteroids. It has been observed that the maximum improvement in Quality of Life and the least Average Cost Effective Ratio were obtained in the case of the combination of Drugs in Group 3. The highest Average Cost Effective Ratio was observed in the case of Group 2 Drugs.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): M A Kuriachan KG Revikumar Andreena Jolly


DMARD, Disease Activity Score (DAS 28), Health Assessment Questionnaire –Disability Index (HAQDI), Quality of Life (QoL).

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us